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http://www.biomedcentral.com/1471-2334/13/416RESEARCH ARTICLE Open AccessIncidence, clinical spectrum, diagnostic features,
treatment and predictors of paradoxical reactions
during antibiotic treatment of Mycobacterium
ulcerans infections
Daniel P O’Brien1,2,3*, Mike Robson4, N Deborah Friedman1, Aaron Walton1, Anthony McDonald5, Peter Callan5,
Andrew Hughes1, Richard Rahdon5 and Eugene Athan1Abstract
Background: Paradoxical reactions from antibiotic treatment of Mycobacterium ulcerans have recently been
recognized. Data is lacking regarding their incidence, clinical and diagnostic features, treatment, outcomes and risk
factors in an Australian population.
Methods: Data was collected prospectively on all confirmed cases of M. ulcerans infection managed at Barwon
Health Services, Australia, from 1/1/1998-31/12/2011. Paradoxical reactions were defined on clinical and histological
criteria and cases were determined by retrospectively reviewing the clinical history and histology of excised lesions.
A Poisson regression model was used to examine associations with paradoxical reactions.
Results: Thirty-two of 156 (21%) patients developed paradoxical reactions a median 39 days (IQR 20-73 days)
from antibiotic initiation. Forty-two paradoxical episodes occurred with 26 (81%) patients experiencing one and 6
(19%) multiple episodes. Thirty-two (76%) episodes occurred during antibiotic treatment and 10 (24%) episodes
occurred a median 37 days after antibiotic treatment. The reaction site involved the original lesion (wound) in 23
(55%), was separate to but within 3 cm of the original lesion (local) in 11 (26%) and was more than 3 cm from
the original lesion (distant) in 8 (19%) episodes. Mycobacterial cultures were negative in 33/33 (100%) paradoxical
episodes. Post-February 2009 treatment involved more cases with no antibiotic modifications (12/15 compared
with 11/27, OR 5.82, 95% CI 1.12-34.07, p = 0.02) and no further surgery (9/15 compared with 2/27, OR 18.75, 95%
CI 2.62-172.73, p < 0.001). Six severe cases received prednisone with marked clinical improvement. On
multivariable analysis, age ≥ 60 years (RR 2.84, 95% CI 1.12-7.17, p = 0.03), an oedematous lesion (RR 3.44, 95%
CI 1.11-10.70, p=0.03) and use of amikacin in the initial antibiotic regimen (RR 6.33, 95% CI 2.09-19.18, p < 0.01)
were associated with an increased incidence of paradoxical reactions.
Conclusions: Paradoxical reactions occur frequently during or after antibiotic treatment of M. ulcerans infections
in an Australian population and may be increased in older adults, oedematous disease forms, and in those
treated with amikacin. Recognition of paradoxical reactions led to changes in management with less surgery,
fewer antibiotic modifications and use of prednisolone for severe reactions.
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Figure 1 Local paradoxical reaction following complete surgical
excision of original lesion (see surgical scar) manifest by the
appearance of 3 new lesions within 3 cm of the surgical site 6
weeks after antibiotic commencement.
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Mycobacterium ulcerans causes necrotizing lesions of
skin and subcutaneous tissue [1]. The necrotic lesions
are characterized by minimal associated inflammation
thought to result from immunomodulatory effects of its
pathogenic toxin mycolactone which impairs both local
and systemic immune responses to the infection [2,3].
Antibiotics are now recommended as initial treatment
for M. ulcerans infections [4,5]. Recently paradoxical
reactions, or immune reconstitution inflammatory syn-
drome reactions, have been recognized to occur follow-
ing antibiotic treatment, [6-9] and can be mistaken for
treatment failure. Although more research needs to be
done to clarify the aetiology of paradoxical reactions, it
is proposed their pathogenesis may involve reversal of
an immune-inhibitory state induced by mycolactone,
[10-12] due to antibiotic mediated killing of the organism
and the secondary reduction in mycolactone levels
[13-15]. This enables the development of an intense
immunological reaction presumably against persisting
dead or viable mycobacteria, [6,8,15] manifest clinically by
worsening of existing, or the appearance of new, lesions
and histologically by the appearance in lesions of intense
inflammation [6,15].
Currently data in an Australian population is lacking
regarding the incidence, clinical and diagnostic features,
treatment, outcomes and predictors of patients developing
paradoxical reactions associated with antibiotic treatment
of M. ulcerans. In this study we describe these factors
amongst a patient cohort treated for M. ulcerans infec-
tions acquired in the Bellarine Peninsula, south-eastern
Australia.
Methods
Data on all confirmed M. ulcerans cases treated at
Barwon Health were collected prospectively from 1/1/
1998-31/12/2011. Cases of paradoxical reactions were
determined by retrospectively reviewing the clinical
history and histology of excised lesions.
A M. ulcerans case was defined by a lesion clinically
suggestive of M. ulcerans plus any of (1) a culture of M.
ulcerans from the lesion, (2) a positive polymerase chain
reaction (PCR) test from a swab or biopsy of the lesion,
or (3) histopathology of an excised lesion showing a
necrotic granulomatous lesion with the presence of
acid-fast bacilli (AFB) consistent with acute M. ulcerans
infection.
Paradoxical reactions were defined by the presence
of one or both of the following features: a) clinical: an
initial improvement on antibiotic treatment in the clinical
appearance of a M. ulcerans lesion followed by deteri-
oration of the lesion or its surrounding tissues, or the
appearance of a new lesion(s), and b) histopathology:
examination of excised tissue from the clinical lesionshowing evidence of an intense inflammatory reaction
consistent with a paradoxical reaction [6]. A ‘severe’
paradoxical reaction was a clinical assessment deter-
mined by the treating clinician.
The site of the paradoxical lesion was defined as ‘wound’
if it occurred in wound margins or involved generalized
induration around the original lesion, ‘local’ if it was
separate to but within 3 cm of the initial lesion or ‘dis-
tant’ if it occurred greater than 3 cm from the initial
lesion (Figures 1 and 2). A patient could have more
than one ‘paradoxical episode’ if there were further new
lesions separated by site or time from the original para-
doxical lesion. The position of a M. ulcerans lesion was
described as distal if it was on or below the elbow or
knee. A ‘major excision’ involved the use of a split skin
graft (SSG) or a vascularised skin and tissue flap to
cover the defect. Positive margins were defined as the
presence of granulomatous inflammation or necrotic
tissue extending to one or more of the surgical excision
margins on histopathological examination [16]. Immune
suppression was defined as current treatment with
immunosuppressive medication (e.g. prednisolone) or
an active malignancy.
Figure 2 Illustration of clinical features representing a wound
paradoxical reaction. a-b: Buruli ulcer lesion posterior calf at
commencement of antibiotic treatment with induration 40x42
mm diameter (a). Lesion after 5 weeks antibiotic treatment
complicated by a paradoxical reaction manifest by increased
induration around lesion (60x40 mm diameter), increased serous
discharge and new ulceration adjacent to initial lesion (b).
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a maximum of 600 mg daily), clarithromycin 7.5 mg/kg
twice daily (up to a maximum of 500 mg twice daily),
ciprofloxacin 500 mg twice daily, moxifloxacin 400 mg
daily, and amikacin 15mg/kg/day. Mycobacterial cultures
were performed using Lowenstein–Jensen media and
incubated for 12 weeks.
Data was analysed using Epi-Info 6 (CDC, Atlanta) and
STATA 12 (StataCorp, Texas, USA). Proportions were
compared using 2×2 tables and the Chi-squared test. A
Kaplan-Meier curve was used to measure the cumulative
incidence of first paradoxical reactions. Outcome data
were censored at the time of a paradoxical reaction, dis-
ease recurrence or 12 months from antibiotic initiation.
A Poisson regression model was used to assess inci-
dence rates and associations of variables with the first
paradoxical episode in a patient. Crude rate ratios were
determined by performing univariable analyses. A multi-
variable analysis was performed including the variables
sex and age a priori and all variables showing strong evi-
dence of an association with paradoxical reactions in the
crude analysis (assessed by p ≤ 0.10). The variable ‘posi-
tive margins’ was not included in the multivariable
model due to missing data (not all patients had surgical
excisions).Ethics
This study was approved by the Barwon Health Research
and Ethics Committee. Verbal patient consent was givenfor the collection and use of data. All data were analysed
anonymously.
Results
From 1/1/1998 until 29/12/2011, 160 patients received
antibiotics at Barwon Health as treatment for M.
ulcerans. One hundred and fifty-six had at least 12-
months follow-up and were included in the study. Two
patients died during treatment and two patients were
lost to follow-up and were not included. Baseline charac-
teristics of the study population are reported in Table 1.
The median duration of antibiotic treatment was 58 days
(IQR 42–90 days).
First paradoxical episode
Thirty-two of 156 (21%) patients developed paradoxical
reactions. Baseline characteristics for patients developing
paradoxical reactions are shown in Table 1. Over a
combined follow-up time of 127.8 years, the rate of first
paradoxical reactions was 25.0 (95% CI 17.7–35.4) per
100 person-years. The cumulative incidence of first
paradoxical reactions, also stratified by age, lesion type
and use of amikacin are shown in Figure 3. The median
time from antibiotic administration to development of
the first reaction was 39 days (IQR 20–73 days). The
number and proportion of patients developing paradoxical
reactions per calendar year is shown in Figure 4.
All paradoxical episodes
There were 42 paradoxical episodes. Twenty-six (81%)
patients experienced one episode and 6 (19%) had mul-
tiple episodes (3 with 2 episodes, 2 with 3 episodes and
1 with 4 episodes). Of those with multiple episodes, four
experienced episodes separated in time and two had
simultaneous episodes separated by site. Thirty-two
(76%) episodes occurred during antibiotic treatment.
Ten (24%) episodes occurred a median of 37 days (range
16-150 days) after antibiotic treatment.
Lesion site
For the 42 paradoxical episodes, the site of the reaction
was wound in 23 (55%), local in 11 (26%) and distant in
8 (19%) episodes.
Eight patients developed new local lesions: for 3
patients this involved 1 lesion, in 4 patients 2 lesions,
and in 1 patient 6 lesions. For those with multiple local
lesions (5 patients), in 3 patients they occurred simul-
taneously and in 2 patients they appeared at separate
times. Seven patients developed new distant lesions:
three developed lesions on a non-contiguous body part;
2 of these involved single lesions on alternate limbs
(one on the left foot with an original on the right foot,
and one on the left lower leg with an original on the
right arm) and one developed 2 lesions on the right
Table 1 Poisson regression model showing adjusted and unadjusted associations between identified factors and first
paradoxical reactions rates
Number (%)
in cohort
Number (%)
experiencing a PR
Follow-up
(years)
Rate per 100
person-years (95% CI)
Crude rate
ratio (95% CI)
p-value* Adjusted rate
ratio (95% CI)
p-value#
Sex
Male 86 (55.1) 15 (17.4) 72.5 20.7 (12.5,34.3) 1 0.26 1 0.64
Female 70 (44.9) 17 (24.3) 55.0 30.8 (19.1,49.5) 1.48 (0.74,2.98) 0.83 (0.38,1.81)
Age (years)
0-<15 13 (8.3) 3 (23.1) 9.9 30.4 (9.8,94.2) 2.94 (0.74,11.76) 0.01 2.77 (0.67,11.38) 0.16
15-<60 62 (39.7) 6 (9.7) 58.1 10.3 (4.6,23.0) 1 1
≥60 81 (51.9) 23 (28.4) 59.8 38.4 (25.5,57.9) 3.72 (1.51,9.14) 2.84 (1.12,7.17) 0.03
Lesion type
Ulcer 137 (87.8) 24 (17.5) 116.0 20.7 (13.9,30.9) 1 0.03 1
Nodule 10 (6.4) 4 (40.0) 6.3 63.3 (23.7,168.6) 3.06 (1.06,8.81) 1.98 (0.57,6.91) 0.29
Oedematous 9 (5.8) 4 (44.4) 5.4 73.9 (27.7,196.8) 3.57 (1.24,10.29) 3.44 (1.11,10.70) 0.03
Lesion site
Upper limb 55 (35.3) 11 (20.0) 44.7 24.6 (13.9,44.4) 1
Lower limb 99 (63.5) 21 (21.2) 80.3 25.9 (16.9,39.7) 1.05 (0.51,2.18) 0.60 - -
Torso 2 (1.3) 0 (0.0) - - -
Lesion position
Proximal 16 (10.3) 2 (12.5) 14.2 14.1 (3.5,56.5) 1 0.35 - -
Distal 140 (89.7) 30 (21.3) 113.6 26.4 (18.5, 37.8) 1.87 ( 0.45,7.82)
Over a joint
No 91 (58.3) 17 (18.7) 76.2 22.5 (13.9,35.9) 1 0.45 - -
Yes 65 (41.7) 15 (23.1) 51.5 29.1 (17.6,48.3) 1.31 (0.65,2.61)
Positive margins
No 36 (32.7) 4 (11.0) 32.5 12.3 (4.6,32.8) 1 0.03 - -
Yes 74 (67.3) 20 (27.0) 56.5 35.4 (22.8,54.8) 2.87 (0.98,8.41)
Any excision
No 42 (27.0) 6 (14.3) 36.5 16.5 (7.4, 36.6) 1 0.20 - -
Yes 114 (73.0) 26 (22.8) 91.3 28.5 (19.4,41.8) 1.72 (0.71,4.20)
Major excision
No 82 (52.6) 11 (13.4) 71.9 15.3 (8.5,27.6) 1 0.01 1 0.14
Yes 74 (47.4) 21 (28.4) 55.9 37.6 (24.5,57.6) 2.45 (1.18,5.09) 1.78 (0.82,3.87)
Diabetes
No 143 (91.7) 27 (18.9) 118.9 22.7 (15.6,33.1) 1 0.09 1 0.77
Yes 13 (8.3) 5 (38.5) 8.8 56.7 (23.6,136.2) 2.50 (0.96,6.49) 1.19 (0.37,3.89)
Immune suppression
No 145 (93.0) 28 (19.3) 120.0 23.3 (16.1,33.8) 1 0.18 - -
Yes 11 (7.1) 4 (36.4) 7.7 51.7 (19.4,137.6) 2.21 (0.78,6.31)
Rifampicin
No 9 (5.8) 2 (22.2) 7.4 26.9 (6.7,107.5) 1 0.92 - -
Yes 147 (94.2) 30 (20.4) 120.3 24.9 (17.4,35.7) 0.93 (0.22,3.88)
Ciprofloxacin
No 55 (35.3) 13 (23.6) 43.5 29.9 (17.4,51.5) 1 0.44 - -
Yes 101 (64.7) 19 (18.8) 84.3 22.5 (14.5,35.7) 0.75 (0.37,1.53)
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Table 1 Poisson regression model showing adjusted and unadjusted associations between identified factors and first
paradoxical reactions rates (Continued)
Clarithromycin
No 108 (69.2) 24 (22.2) 87.1 27.6 (18.5,41.1) 1 0.40 - -
Yes 48 (30.8) 8 (16.7) 40.7 19.7 (9.8,39.3) 0.71 (0.32,1.59)
Ethambutol
No 145 (93.0) 28 (19.3) 120.1 23.3 (16.1,33.8) 1 0.17 - -
Yes 11 (7.1) 4 (36.4) 7.6 52.3 (19.6,139.5) 2.25 (0.79,6.40)
Amikacin
No 151 (96.8) 28 (18.5) 126.0 22.2 (15.3,32.2) 1 <0.001 1 <0.01
Yes 5 (3.2) 4 (80.0) 1.8 228.6 (85.8,609.2) 10.29 (3.61,29.33) 6.33 (2.09,19.18)
Moxifloxacin
No 151 (96.8) 30 (19.9) 124.6 24.1 (16.8,34.4) 1 -
Yes 5 (3.2) 2 (40.0) 3.1 64.0 (16.0,255.8) 2.66 (0.64,11.12) 0.24 -
CI confidence interval, PR paradoxical reaction, *likelihood ratio test, #Wald test.
Figure 3 Cumulative incidence of paradoxical reactions. a: Cumulative incidence of first paradoxical reactions. b: Cumulative incidence of first
paradoxical reactions by age. c: Cumulative incidence of first paradoxical reactions by lesion type. d: Cumulative incidence of first paradoxical
reactions by use of amikacin.
O’Brien et al. BMC Infectious Diseases 2013, 13:416 Page 5 of 10
http://www.biomedcentral.com/1471-2334/13/416
Figure 4 Number and proportion of patients developing paradoxical reactions per calendar year.
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The other 4 patients developed new lesions on an adja-
cent body part to that of the original lesion (e.g. calf to
thigh).
Diagnosis
The diagnosis of paradoxical reactions was made on
clinical and histological criteria in 27 (84%) patients.
For 5 (16%) patients clinical criteria alone were used,
although in 3 (9%) of these cases it was supported by
negative AFB examinations and negative mycobacterial
cultures.
A mycobacterial culture was negative in 33/33 (100%)
paradoxical episodes in 26 patients in which it was
performed at a median of 59 days (IQR 21-80 days) after
antibiotics commenced. All were performed ≥ 2 weeks
after antibiotics commenced. M. ulcerans PCR was posi-
tive in 23/26 (88%) episodes in 21 patients and an AFB
stain was positive in 23/39 (59%) episodes in 31 patients
in which they were done.
Treatment
Paradoxical reactions were managed without changing
the regimen or duration of antibiotic administration in
22 (52%) episodes, antibiotics were prolonged in 10 (24%)
episodes, antibiotics were added and prolonged in 9 epi-
sodes (21%) and an antibiotic added but not prolonged in
1 case (2%). Surgery was performed to manage paradoxical
reactions in 31 (74%) episodes. This involved debridement
in 10 (32%), excision and primary closure in 7 (23%),
excision and SSG in 11 (35%), and excision and flap in
3 (10%) one of whom also had a SSG.
Post-February 2009, when paradoxical reactions were
first recognized in our practice, compared to pre-February
2009, treatment involved more cases with no change in
the antibiotic regimen or duration (12/15 comparedwith 11/27, OR 5.82, 95% CI 1.12–34.07, p = 0.02) and
more cases where no further surgery was performed (9/
15 compared with 2/27, OR 18.75, 95% CI 2.62–172.73,
p < 0.001). There was a trend to less reconstructive surgery
(SSG or flap) performed in the post-February 2009
period (3/15 compared with 11/27, OR 0.36, 95% CI
0.06–1.90, p = 0.18).
Severe paradoxical episodes
Nine of 42 (21%) cases were clinically severe; 3 occurred
prior to prednisolone use and resulted in significant
tissue destruction, further extensive surgery and anti-
biotic changes. For example, from an initial lesion on
the right hand, a patient developed severe inflammation
and necrosis of the hand, fingers and forearm, including
tendons, requiring extensive debridement with a free
tissue flap reconstruction and antibiotics prolonged
until 116 days. Prednisolone was introduced into our
practice to treat severe reactions in June 2010 [17]. Fol-
lowing this 6 severe cases received prednisone at a dose
of 0.5-1 mg/kg daily for 4-6 weeks with marked clinical
improvement in lesion appearances within days to
weeks. Only 2 patients required minimal debridement
of their lesions after prednisolone commencement and
the antimicrobial regimen was not changed nor prolonged
beyond 12 weeks.
Outcomes
All patients with paradoxical lesions experienced healing
of their lesions without disease recurrence after 12
months follow-up from antibiotic commencement.
Predictors of paradoxical reactions
On univariate analyses the following variables were
strongly associated with the development of paradoxical
reactions: age (p = 0.01), lesion type (p = 0.03), major
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use of amikacin (p < 0.001) in the initial antibiotic regi-
men. Diabetes (p = 0.09) showed weaker evidence for an
association (Table 1). On multivariable analysis adjusting
for age, sex, lesion type, major excision, diabetes and the
use of amikacin in the initial antibiotic regimen, age ≥ 60
years (RR 2.84, 95% CI 1.12-7.17, p = 0.03), an
oedematous lesion (RR 3.44, 95% CI 1.11-10.70, p =
0.03) and the use of amikacin in the initial antibiotic
regimen (RR 6.33, 95% CI 2.09-19.18, p < 0.01)
remained strongly associated with the development of
paradoxical reactions (Table 1).
Discussion
This observational study of a large patient cohort treated
with antibiotics for M. ulcerans provides the first compre-
hensive descriptions of the incidence, clinical spectrum,
diagnostic features (microbiological and PCR results),
treatments and outcomes of paradoxical reactions oc-
curring following antibiotic treatment in an Australian
population. It demonstrates that paradoxical reactions
were common, occurring in approximately one in five
patients. They occurred anywhere from the first week of
treatment until 8 months post antibiotic commencement,
although most occurred within 3–10 weeks of antibiotic
initiation. At least one fifth of reactions occurred after
completion of antibiotics, reinforcing other recent evi-
dence from Africa that new clinical symptoms post anti-
biotic treatment should not be assumed to be treatment
failure and recurrent infection [7]. Rates of paradoxical re-
actions in M. ulcerans treated patients are not well de-
scribed, but a rate of 23% was recently described in a
cohort from Africa [8]. Interestingly the rate in our study
is similar to the 16% of HIV patients beginning antiretro-
viral treatment who develop immune reconstitution dis-
ease [18]. In our earlier experience from a smaller cohort
(90 patients) we described paradoxical reactions occur-
ring in 8 (9%) patients [19].
Approximately half the reactions involved an increase
in induration surrounding a lesion, often with increased
amounts of wound discharge. However in nearly one-
fifth of cases, the clinical presentation included the de-
velopment of lesions that were distant from the initial
site, including alternate limbs or body parts. These likely
represent subclinical sites of infection that become evident
secondary to reversal of M. ulcerans induced immune
inhibition upon commencing antibiotics. Reactions could
involve multiple simultaneous lesions, and multiple para-
doxical episodes can also occur in the same patient, sepa-
rated either in site or time.
Although a standard definition of paradoxical reactions
has not been developed our study provides information
that may be useful in distinguishing them from antibiotic
treatment failure. In our experience mycobacterial cultureswere always negative in patients experiencing a paradox-
ical reaction ≥ 2 weeks after antibiotic commencement.
Likewise cultures were negative in paradoxical lesions
recently described by others [7,9]. Conversely both AFB
stains and PCR tests were usually positive, likely from
detection of non-viable M. ulcerans, meaning that when
positive they are not useful in distinguishing between
these two treatment outcomes.
It is critically important to distinguish between paradox-
ical reactions and treatment failure potentially related
to issues such as sub-optimal medication adherence or
drug resistance. We believe that the clinical evolution
of lesions, supported by consistent histopathological
findings in most cases (Figure 5), as well as negative
mycobacterial culture results, strongly suggest that cases
in our study represent true paradoxical reactions and
not progressive disease secondary to antibiotic failure.
This includes 5 patients previously considered to have
antibiotic treatment failures, [16] who were retrospectively
determined in this study to have instead experienced
paradoxical reactions. In these cases the histological
appearances of excised involved tissue showed evidence
of paradoxical reactions [6,15] and differed markedly
from the initial lesions which showed classical appear-
ances of untreated M. ulcerans infections [2]. It is likely
that patients were similarly previously misclassified in
other studies leading to incorrect conclusions that anti-
biotics were ineffective [20,21]. We found no evidence of
bacterial super-infection causing the ‘paradoxical’ lesions
in our study: histopathology of excised lesions showed no
evidence of it and all reactions settled without specific
antibiotic treatment for it.
The recognition of paradoxical reactions has led to a
change in the way M. ulcerans infections are managed in
our practice. It has allowed a significant reduction in the
frequency of cases managed with surgical intervention
(reduced by 19 times) and in the frequency of the
change or prolongation of antibiotic regimens (reduced
by 6 times). There also appears likely to have been a de-
crease in the amount of reconstructive surgery
performed, although due to the low numbers of cases,
the strength of this association was not strong enough
to definitively make this conclusion.
Severe paradoxical reactions can have significant
adverse consequences – a number of patients required
major surgical debridements, often on multiple occa-
sions and requiring reconstructive surgery, resulting in
significant patient morbidity and cost [22]. However
we observed that for severe cases prednisolone effect-
ively controlled the reaction, preserved tissue grafts
and avoided further major surgery without adverse
consequences such as the need to significantly
prolong antibiotics or the development of treatment
failure [17].
Figure 5 Illustration of histological features representing a paradoxical reaction. a-d: Initial lesion before antibiotic treatment showing a
sparse acute inflammatory reaction around necrotic fat and subcutaneous tissue (a) with high numbers of extracellular acid-fast bacilli (in pink)
on Wade-Fite stain (b). After 8 weeks of antibiotic treatment showing a paradoxical reaction manifest by a dense inflammatory reaction including
multinucleated giant cells (c) and no extracellular acid-fast bacilli seen with Wade-Fite stain (d).
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when a paradoxical reaction is suspected, where possible,
a specimen should be sent for urgent histopathological
examination to confirm its presence initially, with myco-
bacterial cultures performed for later confirmation. In
settings where these procedures are not available, if the
clinical appearance is consistent, and other causes such
as suboptimal medication adherence are excluded, then
empirical management for paradoxical reactions would
be a reasonable approach. However there is an urgent
need to develop new diagnostic tests to aid the dis-
tinction between paradoxical reactions and treatment
failure that are feasible, affordable and available in
resource-limited settings where most of the infections
are treated. For mild cases we would recommend that
most can be managed with observation alone, hence
avoiding further surgery or a change in antibiotics. If
necessary limited debridement without reconstructive
surgery is preferred. In severe episodes a course of
prednisolone (0.5–1.0 mg/kg daily tapered over 4–8
weeks) and prolongation of antibiotics to a total of 12
weeks treatment can be considered. Further research
is urgently required to validate these recommenda-
tions in other settings. Currently paradoxical reaction
risk has not been used in our practice as an indica-
tion to avoid antibiotics and treat with surgical exci-
sion alone.To our knowledge, this is the first published study to
examine factors associated with the development of
paradoxical reactions. The incidence appeared to in-
crease in older adults and children; those greater than
60 years had a nearly three times increased rate compared
to younger adults. Children less than 15 years had a
similar increased rate, but limited by low numbers of
children in the study this association was less strong
(p = 0.16). As T-cell mediated immunity is felt to play a
vital role in host immunity against M. ulcerans, [23,24]
possibly the organism has a more powerful inhibitory
effect against this in older adults and children due to
aging or less developed immune systems respectively.
This may allow the organism to replicate more freely
resulting in an increased organism load and secondary
antigenic stimulus, or allow a greater potential for rapid
immune function improvements when the inhibitory
effects of mycolactone toxin are removed with antibi-
otics [13,14].
Oedematous lesions are less common, [1] but are often
severe and rapidly progressive, involving large areas of
the body, and frequently leading to extensive tissue
damage [24]. A three times increased rate of paradoxical
reactions for oedematous lesions was demonstrated in
our study and may result from an increased antigen
load due to the large burden of mycobacteria usually
present in these lesions [24]. In addition, it is probable
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infection allowing it to spread, and once this is aided by
the use of antibiotics an aggressive immune response to
the large antigen load may result. This may be similar to
the recognized increase rate of paradoxical reactions in
HIV-infected people commencing antiretroviral therapy in
those with more extensive or disseminated opportunistic
infections [18], including mycobacterium tuberculosis
[25], thought to be due to increased antigen burden.
Amikacin was associated with greater than a 6 times
increased rate of paradoxical reactions. Amikacin is highly
bactericidal in vitro [26] and this rapid killing of organisms
may act as a strong stimulus for the development of para-
doxical reactions, since the killing of micro-organisms
likely underlies its pathogenesis [15]. Additionally, it may
be that the combination of rifampicin with amikacin is
responsible for the stimulus, as this combination is more
bactericidal than amikacin alone in mouse models [26].
In our study the most commonly used orally adminis-
tered companion drugs to rifampicin (ciprofloxacin and
clarithromycin) were not associated with an increased
rate of paradoxical reactions which may relate to their
known anti-inflammatory properties [27,28]. These find-
ings may offer further advantages to using these antibi-
otics to obtain fully orally administered regimens for M.
ulcerans treatment [19,29]. Furthermore, those who had
antibiotics alone compared to antibiotics plus surgery
were not at an increased risk of paradoxical reactions.
It is known that there is a higher risk of paradoxical
reactions in HIV-infected people commencing antiretro-
viral therapy with increasing levels of immunosuppres-
sion at baseline [18]. In our study on univariable analysis
the rate of paradoxical reactions was double in those
who were immunosuppressed (RR 2.21, 95%CI 0.78–
6.31), but the strength of the association was weakened
(p = 0.18) by the small numbers of immunosuppressed
patients in the cohort (n = 11, 7.1%). Hence further
study with larger cohorts is recommended to further clar-
ify this association.
There are limitations to our study. Firstly, there are no
standardized definitions for paradoxical reactions, and
thus there may be inaccuracies in case ascertainment.
However with 84% of cases confirmed on histology we
feel that our cases accurately represent paradoxical
reactions. Secondly, due to its observational design
there may be other unmeasured confounders not taken
into account in the analysis of associations that could
potentially affect the validity of the findings. Observed
associations should be further studied in prospective
trials. Thirdly there was no data on the size of lesions
and therefore we could not measure the effect of lesion
size on the rate of paradoxical reactions. However, the
type of surgery approximately separates small and large
lesions, as small lesions are amenable to excision andprimary closure whereas larger lesions require SSG or
vascularised flaps (major surgery) to achieve tissue
closure, and this information was included in the
analyses.
Conclusions
Paradoxical reactions occur frequently during or after
antibiotic treatment of M. ulcerans lesions. They mostly
involve changes around the initial infection site but can
be distantly located, and lesions can be multiple with
episodes separated in both site and time. Mycobacterial
cultures are usually negative, but PCR and AFB exami-
nations of involved tissue usually remain positive. Para-
doxical reactions may be increased in older adults,
oedematous forms of disease, and in those treated with
amikacin. Recognition of paradoxical reactions led to
changes in management with less surgery, fewer anti-
biotic modifications and use of prednisolone for severe
reactions.
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